Fig. 4From: Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomesProbability of events of hypoglycemia with incretin-based agents versus placebo. Effect of incretin-based agents on any (a) and severe (b) hypoglycemia was analyzed individually. CI confidence interval, DPP-4I dipeptidyl peptidase-4 inhibitor, GLP-1A glucagon-like peptide-1 agonistBack to article page